This article was originally published in The Gray Sheet
Diagnostic testing services firms complete merger Feb. 26 following an 11-month delay due to Federal Trade Commission concerns that the deal would lead to higher prices for clinical lab service customers in Northern California. A consent order with the agency requires that Quest divest assets worth $4.5 mil. to LabCorp - including leases for 46 patient services centers and four contracts with physician groups in Northern California. The $827 mil. cash and stock purchase of Unilab by Quest was first announced in April 2002 (1"The Gray Sheet" April 8, 2002, p. 19)...
You may also be interested in...
Quest Diagnostics will control 12% of the $3.8 bil. California lab testing market following the acquisition of Unilab Corp. The $1.1 bil. deal was announced April 2, one day after Quest completed its $500 mil. cash acquisition of Amercian Medical Labs (AML)
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.